Pharmaceutical Preparations · CIK 1178670
Developing novel therapeutics based on RNA interference to silence genes causing disease
Comparable business profile · signals at a glance
In the 90 days to Mar 5, 2026: 5 sold $24.0M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 5, 2026 | Garg PushkalEVP Chief R&D | Sell | 740 | $323.55 | $239K |
| Mar 5, 2026 | Garg PushkalEVP Chief R&D | Sell | 654 | $322.33 | $211K |
| Mar 5, 2026 | Garg PushkalEVP Chief R&D | Sell | 510 | $324.59 | $166K |
| Mar 5, 2026 | Garg PushkalEVP Chief R&D | Sell | 500 | $326.08 | $163K |
| Mar 5, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Sell | 233 | $323.25 | $75K |
| Mar 5, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Sell | 153 | $326.24 | $50K |
| Mar 5, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Sell | 148 | $324.60 | $48K |
| Mar 5, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Sell | 124 | $321.81 | $40K |
| Mar 4, 2026 | Greenstreet YvonneChief Executive Officer | Sell | 973 | $323.84 | $315K |
| Mar 4, 2026 | Poulton Jeffrey V.EVP, Chief Financial Officer | Sell | 818 | $323.84 | $265K |
| Mar 4, 2026 | Tanguler TolgaEVP, Chief Commercial Officer | Sell | 767 | $323.84 | $248K |
| Mar 4, 2026 | Garg PushkalEVP Chief R&D | Sell | 767 | $323.84 | $248K |
| Mar 4, 2026 | Greenstreet YvonneChief Executive Officer | Sell | 444 | $323.01 | $143K |
| Mar 4, 2026 | Poulton Jeffrey V.EVP, Chief Financial Officer | Sell | 374 | $323.01 | $121K |
| Mar 4, 2026 | Greenstreet YvonneChief Executive Officer | Sell | 368 | $321.82 | $118K |
| Mar 4, 2026 | Garg PushkalEVP Chief R&D | Sell | 350 | $323.01 | $113K |
| Mar 4, 2026 | Tanguler TolgaEVP, Chief Commercial Officer | Sell | 350 | $323.01 | $113K |
| Mar 4, 2026 | Greenstreet YvonneChief Executive Officer | Sell | 345 | $324.88 | $112K |
| Mar 4, 2026 | Poulton Jeffrey V.EVP, Chief Financial Officer | Sell | 309 | $321.82 | $99K |
| Mar 4, 2026 | Poulton Jeffrey V.EVP, Chief Financial Officer | Sell | 291 | $324.88 | $95K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Coverage (30d): 1 reputable article.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗